Yin Kean

1.4k total citations · 1 hit paper
12 papers, 969 citations indexed

About

Yin Kean is a scholar working on Infectious Diseases, Surgery and Epidemiology. According to data from OpenAlex, Yin Kean has authored 12 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Surgery and 6 papers in Epidemiology. Recurrent topics in Yin Kean's work include Microscopic Colitis (6 papers), Clostridium difficile and Clostridium perfringens research (6 papers) and Helicobacter pylori-related gastroenterology studies (4 papers). Yin Kean is often cited by papers focused on Microscopic Colitis (6 papers), Clostridium difficile and Clostridium perfringens research (6 papers) and Helicobacter pylori-related gastroenterology studies (4 papers). Yin Kean collaborates with scholars based in United States, France and United Kingdom. Yin Kean's co-authors include Mark A. Miller, Sherwood L. Gorbach, Thomas Louie, Oliver A. Cornely, Kathleen M. Mullane, P.S. Sears, Farah Babakhani, Stuart Johnson, Adam Cheknis and Kristin Nagaro and has published in prestigious journals such as New England Journal of Medicine, The Journal of Chemical Physics and Journal of Clinical Oncology.

In The Last Decade

Yin Kean

12 papers receiving 956 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

2023 132 citations Yohann Loriot, Nobuaki Matsubara et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Yin Kean

Since Specialization

Citations

This map shows the geographic impact of Yin Kean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yin Kean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yin Kean more than expected).

Fields of papers citing papers by Yin Kean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yin Kean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yin Kean. The network helps show where Yin Kean may publish in the future.

Co-authorship network of co-authors of Yin Kean

This figure shows the co-authorship network connecting the top 25 collaborators of Yin Kean. A scholar is included among the top collaborators of Yin Kean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yin Kean. Yin Kean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma breakdown → 2023 ·New England Journal of Medicine ·Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert Huddart, Earle F. Burgess, Nadine Houédé, Séverine Banek, Valentina Guadalupi, Ja Hyeon Ku, Begoña P. Valderrama, Ben Tran, Spyros Triantos, Yin Kean, Sydney Akapame, Kris Deprince, Sutapa Mukhopadhyay, Nicole L. Stone, Arlene O. Siefker‐Radtke	132
2	2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt) 2023 ·Annals of Oncology ·Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, Robert Huddart, Earle F. Burgess, Mustafa Özgüroğlu, Begoña P. Valderrama, Spyros Triantos, Sydney Akapame, Yin Kean, Kris Deprince, (unknown), Yohann Loriot	1
3	Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors 2014 ·Clinical Infectious Diseases ·Ralph B. D’Agostino, Sylva H. Collins, Karol M. Pencina, Yin Kean, Sherwood L. Gorbach	65
4	Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy 2013 ·BMC Infectious Diseases ·Mark A. Miller, Thomas Louie, Kathleen M. Mullane, Karl Heinz Weiss, Arnold Lentnek, Yoav Golan, Yin Kean, (unknown)	116
5	Resolution ofClostridium difficile–Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin 2013 ·Journal of Clinical Oncology ·Oliver A. Cornely, Mark A. Miller, B. Fantin, Kathleen M. Mullane, Yin Kean, Sherwood L. Gorbach	78
6	Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials 2012 ·Clinical Infectious Diseases ·Derrick W. Crook, A. Sarah Walker, Yin Kean, Karl Weiss, Oliver A. Cornely, Mark A. Miller, Roberto Esposito, Thomas Louie, Nicole Stoesser, Bernadette Young, Brian Angus, Sherwood L. Gorbach, Tim Peto	197
7	Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain 2012 ·Clinical Infectious Diseases ·(unknown), Susan P. Sambol, Adam Cheknis, Kristin Nagaro, Yin Kean, P.S. Sears, Farah Babakhani, Stuart Johnson, Dale N. Gerding	151
8	Clostridium difficile-associated diarrhea in cancer patients treated with fidaxomicin or vancomycin. 2012 ·Journal of Clinical Oncology ·Oliver A. Cornely, Mark A. Miller, B. Fantin, Kathleen M. Mullane, Yin Kean, Sherwood L. Gorbach	3
9	Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer 2001 ·Journal of Clinical Oncology ·Fadlo R. Khuri, James R. Rigas, Robert A. Figlin, Richard J. Gralla, Dong M. Shin, Reginald F. Munden, (unknown), (unknown), Yin Kean, Steven D. Reich, Waun Ki Hong	107
10	Self-perceived Health and 5-Year Mortality Risks among the Elderly in Shanghai, China 1998 ·American Journal of Epidemiology ·Erhui Yu, Yin Kean, Donald J. Slymen, (unknown), Ming Zhang, Robert Katzman	84
11	Filial piety and caregiving burden in Shanghai, People's Republic of China 1997 ·Digital Commons - Lingnan (Lingnan University) ·William T. Liu, Elena S. H. Yu, (unknown), Yin Kean	1
12	Binary icosahedral clusters: Atom and electron counting rules 1993 ·The Journal of Chemical Physics ·Boon K. Teo, Hong Zhang, Yin Kean, (unknown), Xiaobo Shi	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact